Center for Financial Planning Inc. Cuts Position in Danaher Corporation $DHR

Center for Financial Planning Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 10.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,057 shares of the conglomerate’s stock after selling 349 shares during the period. Center for Financial Planning Inc.’s holdings in Danaher were worth $604,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in DHR. Sierra Ocean LLC increased its stake in shares of Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock worth $29,000 after buying an additional 76 shares during the period. Red Tortoise LLC increased its stake in shares of Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the period. Ramirez Asset Management Inc. purchased a new stake in shares of Danaher during the second quarter worth approximately $40,000. Costello Asset Management INC purchased a new stake in shares of Danaher during the first quarter worth approximately $41,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of Danaher by 53.8% during the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock worth $42,000 after buying an additional 71 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR opened at $215.63 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm has a market cap of $152.31 billion, a PE ratio of 44.46, a price-to-earnings-growth ratio of 3.28 and a beta of 0.77. The company’s 50 day simple moving average is $203.41 and its 200-day simple moving average is $199.47. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm posted $1.71 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Rothschild Redb lowered shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Barclays increased their price target on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. JPMorgan Chase & Co. increased their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Cowen reiterated a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Finally, Wells Fargo & Company reiterated a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.